Giada Rizzi

973 total citations
39 papers, 713 citations indexed

About

Giada Rizzi is a scholar working on Surgery, Physiology and Pathology and Forensic Medicine. According to data from OpenAlex, Giada Rizzi has authored 39 papers receiving a total of 713 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Surgery, 12 papers in Physiology and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Giada Rizzi's work include Nausea and vomiting management (36 papers), Anesthesia and Pain Management (18 papers) and Chemotherapy-induced organ toxicity mitigation (10 papers). Giada Rizzi is often cited by papers focused on Nausea and vomiting management (36 papers), Anesthesia and Pain Management (18 papers) and Chemotherapy-induced organ toxicity mitigation (10 papers). Giada Rizzi collaborates with scholars based in United States, Switzerland and Germany. Giada Rizzi's co-authors include Antônio Rossi, Richard J. Gralla, Maria Elisa Borroni, Igor Bondarenko, Matti Aapro, Paul J. Hesketh, Lee S. Schwartzberg, Anna Alyasova, Karin Jordan and Snežana Bošnjak and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Giada Rizzi

37 papers receiving 685 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Giada Rizzi United States	10	676	402	92	72	43	39	713
Maria Elisa Borroni United States	7	380 0.6×	223 0.6×	53 0.6×	39 0.5×	26 0.6×	10	401
H. P. Sleeboom Netherlands	3	351 0.5×	179 0.4×	75 0.8×	36 0.5×	31 0.7×	3	387
Masahiko Nakao Japan	9	254 0.4×	142 0.4×	21 0.2×	42 0.6×	47 1.1×	21	320
Bernardo Marzano Italy	9	152 0.2×	75 0.2×	134 1.5×	15 0.2×	27 0.6×	13	326
Karsten Bech Denmark	9	204 0.3×	27 0.1×	29 0.3×	18 0.3×	41 1.0×	13	301
Timothy L. Beard United States	7	275 0.4×	37 0.1×	52 0.6×	16 0.2×	46 1.1×	10	335
Hening Zhai China	8	388 0.6×	207 0.5×	67 0.7×	1 0.0×	23 0.5×	19	470
L. Moreno Spain	6	165 0.2×	38 0.1×	37 0.4×	12 0.2×	7 0.2×	17	249
Áron Altorjay Hungary	9	216 0.3×	32 0.1×	14 0.2×	9 0.1×	28 0.7×	37	308
Susanne Toussaint Germany	8	102 0.2×	13 0.0×	75 0.8×	53 0.7×	22 0.5×	17	235

Countries citing papers authored by Giada Rizzi

Since Specialization

Citations

This map shows the geographic impact of Giada Rizzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giada Rizzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giada Rizzi more than expected).

Fields of papers citing papers by Giada Rizzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giada Rizzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giada Rizzi. The network helps show where Giada Rizzi may publish in the future.

Co-authorship network of co-authors of Giada Rizzi

This figure shows the co-authorship network connecting the top 25 collaborators of Giada Rizzi. A scholar is included among the top collaborators of Giada Rizzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giada Rizzi. Giada Rizzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Karthaus, Meinolf, Daniel L. Voisin, Giada Rizzi, & Tudor–Eliade Ciuleanu. (2020). Phase 3 Study of Palonosetron IV Infusion Vs. IV Bolus for Chemotherapy-Induced Nausea and Vomiting Prophylaxis After Highly Emetogenic Chemotherapy. Journal of Pain and Symptom Management. 60(3). 568–576. 1 indexed citations

Kurteva, G., et al.. (2019). Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. European Journal of Pharmaceutical Sciences. 139. 105041–105041. 5 indexed citations

Schwartzberg, Lee, Eric Roeland, Zoran Andrić, et al.. (2018). Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Annals of Oncology. 29(7). 1535–1540. 24 indexed citations

Bošnjak, Snežana, Ljiljana Stamatović, Maria Elisa Borroni, Giada Rizzi, & Karin Jordan. (2018). Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy. International Journal of Gynecological Cancer. 28(6). 1153–1161. 6 indexed citations

Rugo, Hope S., Giorgia Rossi, Giada Rizzi, & Matti Aapro. (2017). Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials. The Breast. 33. 76–82. 8 indexed citations

Schwartzberg, Lee S., et al.. (2017). Phase 3 safety evaluation of an intravenous formulation of NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron. Annals of Oncology. 28. v545–v545. 4 indexed citations

Jordan, Karin, et al.. (2016). Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. Supportive Care in Cancer. 24(11). 4617–4625. 13 indexed citations

Aapro, Matti, Meinolf Karthaus, Lee S. Schwartzberg, et al.. (2016). NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Supportive Care in Cancer. 25(4). 1127–1135. 31 indexed citations

Aapro, Matti, Karin Jordan, Richard J. Gralla, et al.. (2016). Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients. Journal of Geriatric Oncology. 8(1). 56–63. 7 indexed citations

10.

Karthaus, Meinolf, Tibor Csőszi, Vito Lorusso, et al.. (2015). Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC). Supportive Care in Cancer. 23(10). 2917–2923. 16 indexed citations

11.

Rugo, Hope, Matti Aapro, Giorgia Rossi, & Giada Rizzi. (2015). PO112EFFICACY OF NEPA, THE FIRST COMBINATION ANTIEMETIC AGENT, IN PATIENTS WITH BREAST CANCER RECEIVING ANTHRACYCLINE/CYCLOPHOSPHAMIDE (AC) OR NON-AC CHEMOTHERAPY. The Breast. 24. S60–S60. 2 indexed citations

12.

Jordan, Karin, Richard J. Gralla, & Giada Rizzi. (2015). Should all antiemetic guidelines recommend adding a NK₁ receptor antagonist (NK₁RA) in patients (pts) receiving carboplatin (carbo)? Efficacy evaluation of NEPA, a fixed combination of the NK₁RA, netupitant, and palonosetron.. Journal of Clinical Oncology. 33(15_suppl). 9597–9597. 5 indexed citations

13.

Aapro, Matti, H. S. Rugo, Antônio Rossi, et al.. (2014). A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Annals of Oncology. 25(7). 1328–1333. 180 indexed citations

14.

Gralla, Richard J., Snežana Bošnjak, Christina Balser, et al.. (2014). A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Annals of Oncology. 25(7). 1333–1339. 141 indexed citations

15.

Locatelli, Federica, Marco Pozzi, Giada Rizzi, et al.. (2014). Pharyngeal spasticity due to dantrolene. Journal of Clinical Pharmacy and Therapeutics. 39(4). 449–451.

16.

Jahn, Patrick, Karin Jordan, & Giada Rizzi. (2014). 173 Does preventing nausea correlate with an improvement in functioning for patients with cancer? Evaluation of NEPA, a novel fixed-dose antiemetic combination. European Journal of Oncology Nursing. 18. S54–S55. 1 indexed citations

17.

Aapro, Matti, Richard J. Gralla, Lee S. Schwartzberg, et al.. (2014). Multicycle Efficacy and Safety of Nepa, a Fixed-Dose Antiemetic Combination of Netupitant and Palonosetron, in Patients Receiving Chemotherapy of Varying Emetogenicity. Annals of Oncology. 25. iv518–iv518. 2 indexed citations

18.

Aapro, Matti, et al.. (2013). Impact on patients’ daily life activities of NEPA, the oral fixed-dose combination of netupitant, a new NK₁ receptor antagonist (RA), and palonosetron (PALO) plus dexamethasone (DEX) versus PALO plus DEX for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC).. Journal of Clinical Oncology. 31(31_suppl). 66–66. 4 indexed citations

19.

Jordan, Karin, et al.. (2013). NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting (CINV) following repeated chemotherapy cycles: Results of a phase III trial.. Journal of Clinical Oncology. 31(15_suppl). e20716–e20716. 2 indexed citations

20.

Checchi, L, et al.. (1989). [Control of postoperative pain in periodontology].. PubMed. 57(6). 107–11.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact